0.55Open0.55Pre Close0 Volume12 Open Interest30.00Strike Price0.00Turnover395.33%IV252.36%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type0.1837Delta0.0336Gamma15.76Leverage Ratio-0.0537Theta0.0006Rho2.90Eff Leverage0.0053Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet